

ARC-WA Site Assessment Visits Across Nigeria, Sierra Leone, and Liberia

10 Dec 2024 | Updates | 2 min read | Admin



Over the past two to three weeks, the TCP team has conducted multiple visits to clinical trial sites across the designated countries as part of the Track A efforts under the ARC-WA project. These visits are a critical step in assessing the current infrastructure, capabilities, and readiness of the sites. The primary objective is to evaluate and identify a selection of clinical trial sites that will undergo further capacity development, ensuring they are well-prepared to support future large-scale vaccine trials.

This initiative is specifically aimed at strengthening sites in Lassa fever endemic areas to facilitate their participation in a potential Phase 3 Lassa fever vaccine trial. By focusing on this rigorous site selection and preparation process, we are laying the groundwork for high-quality research that could contribute significantly to the fight against Lassa fever and enhance regional capacity for conducting advanced clinical trials.